Peptide Functionalization of Silicon for Detection and Classification of Prostatic Cells

The development of simple, rapid, and low cost methods for early detection, identification, and measurement of multiple biomarkers remains a challenge to improve diagnosis, treatment monitoring, and prognosis of cancer. Biosensing technology, combining the properties of biological systems with functional advanced materials, guarantees rapid, reproducible, and highly sensitive cell detection. In this study, we developed silicon-based biochips for prostate cancer PC3 cells detection by using cytokeratin 8/18 and Urotensin Receptor (UTR) as markers in order to obtain a biochip-based diagnostic system. Spectroscopic ellipsometry and fluorescence microscopy were used to characterize surface homogeneity and chemical properties. Cell detection was investigated by optical microscopy. Moreover, synthetic fluorescently labeled peptides were prepared and used for developing faster and lower-cost identification assay compared with classic ELISA immunoassay. Results showed an effective immobilization of PC3 cells on silicon surface and the specific recognition of these cells by fluorescent Urotensin II (4–11). In conclusion, this strategy could be really useful as diagnostic system for prostate cancer.

[1]  David Wild,et al.  The immunoassay handbook : theory and applications of ligand binding, ELISA and related techniques , 2013 .

[2]  P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .

[3]  Ivo Rendina,et al.  Silicon-Based Technology for Ligand-Receptor Molecular Identification , 2012 .

[4]  Onur Tigli,et al.  Biosensors in the small scale: methods and technology trends. , 2013, IET nanobiotechnology.

[5]  E. Novellino,et al.  Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells , 2011, Journal of cellular biochemistry.

[6]  J. Švitel,et al.  Optical biosensors , 2016, Essays in biochemistry.

[7]  B. Lytton,et al.  The role of vertebral veins in the dissemination of prostatic carcinoma. , 1981, The Journal of urology.

[8]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[9]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[10]  R. Franco,et al.  Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[11]  N. Clarke,et al.  Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells , 2000, British Journal of Cancer.

[12]  Hwee Tong Tan,et al.  Serum autoantibodies as biomarkers for early cancer detection , 2009, The FEBS journal.

[13]  Mun'delanji C. Vestergaard,et al.  An Overview of Label-free Electrochemical Protein Sensors , 2007, Sensors.

[14]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[15]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[16]  M. Zelen,et al.  Inferring the natural time history of breast cancer: Implications for tumor growth rate and early detection , 2005, Breast Cancer Research and Treatment.

[17]  A F Collings,et al.  Biosensors: recent advances , 1997 .

[18]  William J Catalona,et al.  What to do with an abnormal PSA test. , 2008, The oncologist.

[19]  M. Marra,et al.  Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. , 2005, Current drug targets.

[20]  G. Mattson,et al.  A practical approach to crosslinking , 1993, Molecular Biology Reports.

[21]  R. Subramanian,et al.  Fabrication of impedimetric sensors for label-free Point-of-Care immunoassay cardiac marker systems, with passive microfluidic delivery , 2006, 2006 International Conference of the IEEE Engineering in Medicine and Biology Society.

[22]  W. Oh,et al.  PC 3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma , 2012 .

[23]  C. Logothetis,et al.  Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer , 2008, Clinical Cancer Research.

[24]  E. Novellino,et al.  A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.

[25]  J. Goding.  Use of staphylococcal protein A as an immunological reagent. , 1978, Journal of immunological methods.

[26]  C. Stephan,et al.  Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.

[27]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[28]  W. Oh,et al.  PC3 is a cell line characteristic of prostatic small cell carcinoma , 2011, The Prostate.

[29]  M. Marra,et al.  R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation , 2007, Journal of cellular physiology.

[30]  Jongyoon Han,et al.  An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. , 2014, The Analyst.